Latest updates
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson's patients who have a GBA-1...
Ambroxol – new real-world data
Ambroxol is a cough medication that Cure Parkinson's is repurposing for potential use in treating Parkinson's, and recently published data provides further support for...
The AIM-PD trial (ambroxol)
Supported by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2...
DENALI and Biogen team up against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen.
A greater role for the parkinson’s GBA gene protein?
There is a great deal of variability between each person affected by Parkinson's. Better knowledge of these variables could not only provide insights...